WO2008088846A3 - Substance p and analogs thereof as an immunogenic composition adjuvant - Google Patents

Substance p and analogs thereof as an immunogenic composition adjuvant Download PDF

Info

Publication number
WO2008088846A3
WO2008088846A3 PCT/US2008/000621 US2008000621W WO2008088846A3 WO 2008088846 A3 WO2008088846 A3 WO 2008088846A3 US 2008000621 W US2008000621 W US 2008000621W WO 2008088846 A3 WO2008088846 A3 WO 2008088846A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
analogs
immunogenic composition
adjuvant
composition adjuvant
Prior art date
Application number
PCT/US2008/000621
Other languages
French (fr)
Other versions
WO2008088846A2 (en
Inventor
Hal Siegel
Original Assignee
Immuneregen Biosciences Inc
Hal Siegel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuneregen Biosciences Inc, Hal Siegel filed Critical Immuneregen Biosciences Inc
Priority to CA002675753A priority Critical patent/CA2675753A1/en
Priority to EP08724582A priority patent/EP2125869A2/en
Publication of WO2008088846A2 publication Critical patent/WO2008088846A2/en
Publication of WO2008088846A3 publication Critical patent/WO2008088846A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Substance P and bioactive analogs thereof can be used as an adjuvant with immunogenic compositions to enhance the immunizing properties of the immunogenic compositions. In some embodiments, the amount of antigen needed in each dose of immunogenic composition is decreased due to the adjuvant activity of the substance P analogs.
PCT/US2008/000621 2007-01-18 2008-01-17 Substance p and analogs thereof as an immunogenic composition adjuvant WO2008088846A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002675753A CA2675753A1 (en) 2007-01-18 2008-01-17 Substance p and analogs thereof as an immunogenic composition adjuvant
EP08724582A EP2125869A2 (en) 2007-01-18 2008-01-17 Substance p and analogs thereof as an immunogenic composition adjuvant

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US88556207P 2007-01-18 2007-01-18
US60/885,562 2007-01-18
US91535807P 2007-05-01 2007-05-01
US60/915,358 2007-05-01
US95571207P 2007-08-14 2007-08-14
US60/955,712 2007-08-14

Publications (2)

Publication Number Publication Date
WO2008088846A2 WO2008088846A2 (en) 2008-07-24
WO2008088846A3 true WO2008088846A3 (en) 2008-11-06

Family

ID=39636581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000621 WO2008088846A2 (en) 2007-01-18 2008-01-17 Substance p and analogs thereof as an immunogenic composition adjuvant

Country Status (3)

Country Link
EP (1) EP2125869A2 (en)
CA (1) CA2675753A1 (en)
WO (1) WO2008088846A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8321012B2 (en) 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation

Also Published As

Publication number Publication date
WO2008088846A2 (en) 2008-07-24
EP2125869A2 (en) 2009-12-02
CA2675753A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
IN2012DN01898A (en)
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
UA96076C2 (en) Use of trans-clomiphene
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
WO2008128049A3 (en) Tetrahydrobiopterin compositions and methods of measuring
PH12014501835A1 (en) Novel adjuvant compositions
EP2492301A4 (en) Novel co-modified organopolysiloxane
WO2008152822A1 (en) Medicinal agent
JO2831B1 (en) Quinuclidine Carbonate Derivatives and Medicinal Composition Thereof
EA201070200A1 (en) COMPOSITIONS CONTAINING PNEUMOCOCCAL ANTIGENS
ITMI20041820A1 (en) COMPOSITION IN MICRO-PELLETS WITH CONTROLLED RELEASE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES, PREPARATION PROCEDURE AND RELATED USE IN THE ZOOTECHNICAL SECTOR.
EA201390832A1 (en) BIFIDOBACTERIUM CECT 7765 AND ITS APPLICATION FOR THE PREVENTION AND / OR TREATMENT OF EXCESSIVE WEIGHT, OBESITY AND CONCERNING DISEASES
CO6751287A2 (en) Mycobacterial antigenic composition
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2014030770A3 (en) Copolymer having carbosiloxane dendrimer structure and hydrophilic group
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
WO2012027073A8 (en) Saccharide siloxanes stable in aqueous environments and methods for the preparation and use of such saccharide siloxanes
WO2012006342A3 (en) Ceramide-like glycolipid-associated bacterial vaccines and uses thereof
MX366051B (en) Porcine reproductive and respiratory syndrome virus compositions and uses thereof.
WO2008008541A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
CA2800424C (en) B1,2 cyclic beta glucan compound for use to enhance adaptive immunity by activation of dendritic cells
WO2008088846A3 (en) Substance p and analogs thereof as an immunogenic composition adjuvant
BRPI0813420A2 (en) use of a preparation, composition, cosmetic method of weight loss treatment, and method of a therapeutic treatment to reduce the amount of lipids stored by adipocytes
WO2013019383A3 (en) Soft solid antiperspirant compositions including stearyl alcohol and cetyl and/or myristyl alcohol
UA42625U (en) Composition for treatment of diseases of joints

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08724582

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2675753

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008724582

Country of ref document: EP